A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Summary

This research study is studying a drug combination as a possible treatment for anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. The drugs involved in this study are: * Alectinib * Cobimetinib

Timeline

Start

2017-09-14

Primary completion

2029-01-01

Completion

2031-01-01

Drugs

Indications